An international, multicentre, interventional, randomised, assessor-blinded trial to MAXimise the METHotrexate therapy potential in patients with active rheumatoid arthritis (MethMax trial): study protocol for a randomised controlled trial

Abstract Background Methotrexate (MTX) is recommended as first-line therapy in patients with rheumatoid arthritis (RA), proven to be effective, safe and inexpensive. However, a significant proportion of patients does not achieve disease remission with MTX monotherapy. Main reasons include insufficie...

Descrición completa

Detalles Bibliográficos

Principais autores:	Karolina Anderle, Daniela Sieghart, Martina Durechova, François Bonnay, Andreas Kerschbaumer, Katerina Chatzidionysiou, Rachel Knevel, Costantino Pitzalis, Siri Lillegraven, Espen A. Haavardsholm, Eirik Klami Kristianslund, Catalin Codreanu, Claudiu Popescu, Elisa Gremese, Sabina de Geest, Agnes Kocher, Souzi Makri, Daniel Aletaha, Helga Lechner-Radner, the SQUEEZE Consortium
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2026-03-01
Series:	Trials
Assuntos:	Methotrexate Rheumatoid arthritis Patient-reported outcomes Clinical disease activity Explorative biomarkers Adherence
Acceso en liña:	https://doi.org/10.1186/s13063-026-09519-4
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!